Quidel Corporation (NASDAQ:QDEL) SVP Ratan S. Borkar sold 24,781 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $40.05, for a total transaction of $992,479.05. Following the completion of the sale, the senior vice president now owns 10,811 shares in the company, valued at $432,980.55. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Quidel Corporation (NASDAQ:QDEL) traded up $0.21 during trading hours on Wednesday, reaching $39.80. The company’s stock had a trading volume of 246,540 shares, compared to its average volume of 299,115. The company has a debt-to-equity ratio of 0.70, a current ratio of 6.28 and a quick ratio of 5.68. Quidel Corporation has a 1 year low of $18.25 and a 1 year high of $45.55.

Quidel (NASDAQ:QDEL) last announced its quarterly earnings results on Wednesday, November 1st. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.21). Quidel had a negative net margin of 2.33% and a negative return on equity of 2.36%. The firm had revenue of $50.89 million during the quarter, compared to analysts’ expectations of $50.47 million. During the same quarter in the prior year, the business earned $0.10 EPS. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. sell-side analysts anticipate that Quidel Corporation will post 0.6 EPS for the current year.

A number of brokerages have issued reports on QDEL. Canaccord Genuity reiterated a “buy” rating and set a $48.00 price target on shares of Quidel in a research note on Wednesday, October 25th. Zacks Investment Research raised Quidel from a “hold” rating to a “buy” rating and set a $50.00 price objective for the company in a research report on Friday, October 13th. Barclays upped their price target on Quidel from $45.00 to $49.00 and gave the company an “overweight” rating in a report on Thursday, November 2nd. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $50.00 price target on shares of Quidel in a report on Friday, November 3rd. Finally, BidaskClub raised Quidel from a “sell” rating to a “hold” rating in a report on Saturday. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $48.80.

Several hedge funds have recently made changes to their positions in QDEL. Acrospire Investment Management LLC boosted its stake in shares of Quidel by 42.2% during the second quarter. Acrospire Investment Management LLC now owns 3,678 shares of the company’s stock valued at $100,000 after acquiring an additional 1,091 shares during the last quarter. Legal & General Group Plc boosted its stake in Quidel by 4.6% in the 1st quarter. Legal & General Group Plc now owns 6,931 shares of the company’s stock worth $157,000 after buying an additional 306 shares during the last quarter. Great West Life Assurance Co. Can boosted its stake in Quidel by 162.7% in the 3rd quarter. Great West Life Assurance Co. Can now owns 4,642 shares of the company’s stock worth $204,000 after buying an additional 2,875 shares during the last quarter. Jane Street Group LLC acquired a new stake in Quidel in the 3rd quarter worth about $205,000. Finally, Russell Investments Group Ltd. acquired a new stake in Quidel in the 2nd quarter worth about $209,000. Institutional investors and hedge funds own 92.67% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/06/insider-selling-quidel-corporation-qdel-svp-sells-24781-shares-of-stock.html.

Quidel Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Insider Buying and Selling by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.